The amount of innovation we have seen in response to the pandemic has been nothing short of extraordinary. New vaccine platforms that have been in development for decades – most notably mRNA-based and DNA-based therapeutics – have finally advanced, with two mRNA-based vaccines, Moderna and Pfizer, obtaining emergency use authorization within the same year the virus appeared.

Just one year after the U.S. economy shut down, more than 95 million Americans (29% of the country’s population) are fully vaccinated, and only consumer hesitancy can hold us back from vaccinating the large majority of Americans by summer. In fact, our vaccine acquisition and distribution strategy has been so successful, we are now planning to release vaccine supply to other countries, and manufacturers are starting to pull back production.

This article was originally published on